Big Pharma Outbids Public Investors: Step-Ups in Biopharma Exits
This article was originally published in Start Up
Executive Summary
Biotechs exiting via selling out to Big Pharma have been averaging far higher multiples than those exiting via IPO.
You may also be interested in...
Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019
Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.
Private Equity: One Company's Surprising Route toward Value Creation
In an unusual twist, a biotech is turning to private equity for its initial institutional financing, in the belief that it will offer a better route to long-term value creation than venture capital.
Private Equity: One Company's Surprising Route toward Value Creation
In an unusual twist, a biotech is turning to private equity for its initial institutional financing, in the belief that it will offer a better route to long-term value creation than venture capital.